CompletedPhase 2NCT00135720
Study of Etanercept (Enbrel) in the Treatment of Pemphigus Vulgaris
Studying Pemphigus vulgaris
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Massachusetts General Hospital
- Principal Investigator
- Alexandra B Kimball, MD, MPHCURTIS - Clinical Unit for Research Trials in Skin at Partners (MGH and BWH)
- Intervention
- Enbrel (Etanercept)(drug)
- Enrollment
- 12 enrolled
- Eligibility
- 18-65 years · All sexes
- Timeline
- 2004 – 2007
Study locations (1)
- Clinical Unit for Research Trials in Skin, Boston, Massachusetts, United States
Collaborators
Brigham and Women's Hospital · Stanford University
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00135720 on ClinicalTrials.govOther trials for Pemphigus vulgaris
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07384221Periodontal Status and Disease Severity in Pemphigus Vulgaris PatientsSaglik Bilimleri Universitesi
- RECRUITINGPHASE1, PHASE2NCT04422912A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)Cabaletta Bio
- RECRUITINGNCT02753777Autoimmune Blistering Diseases StudyUniversity of Pennsylvania